Alnylam Pharmaceuticals Inc (ALNY)vsGH Research PLC (GHRS)
ALNY
Alnylam Pharmaceuticals Inc
$313.04
-0.19%
HEALTHCARE · Cap: $39.26B
GHRS
GH Research PLC
$26.17
-7.83%
HEALTHCARE · Cap: $1.95B
Smart Verdict
WallStSmart Research — data-driven comparison
ALNY leads profitability with a 12.6% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
GHRS
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.3%
Fair Value
$2354.68
Current Price
$313.04
$2041.64 discount
Intrinsic value data unavailable for GHRS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 38.8x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bull Case : GHRS
The strongest argument for GHRS centers on Debt/Equity, Altman Z-Score.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 74.1x leaves little room for execution misses.
Bear Case : GHRS
The primary concerns for GHRS are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ALNY profiles as a growth stock while GHRS is a value play — different risk/reward profiles.
GHRS carries more volatility with a beta of 1.31 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (65/100 vs 23/100) and 96.4% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
GH Research PLC
HEALTHCARE · BIOTECHNOLOGY · USA
GH Research PLC is a clinical-stage biopharmaceutical company specializing in the development of psilocybin-based therapies targeted at psychiatric and neurodegenerative disorders. With a strong pipeline designed to meet significant unmet needs in mental health treatment, the company is led by an experienced team dedicated to advancing innovative therapeutic solutions. By leveraging its unique scientific approach, GH Research aims to transform treatment paradigms and improve patient outcomes, positioning itself as a potential leader in the burgeoning mental health therapeutics market.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?